undamentalytics Newsletter
Sign in

BIO KEY International Inc (BKYI) stock

Add to watchlist

Add holding +

NASDAQ: BKYI Nasdaq Application Software

D Fundamentals grade

BIO KEY International Inc is a US-listed company in the application software industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for BIO KEY International Inc is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

BIO KEY International Inc valuation: adjust assumptions and compare models →

Value diary

Our note on each quarter BIO KEY International files

Where BIO KEY International stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $7m, down 3.1% on a year earlier, against growth of 1.9% a quarter earlier. That puts it 113 of 124 for growth among the application software companies we cover. Free-cash-flow margin fell to -62.1% from -51.0% a year earlier. Operating margin narrowed to -86.4% from -51.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks.

Our model value for BIO KEY International is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

BIO KEY International Inc's trailing-twelve-month revenue fell 3.1% year on year, with a free-cash-flow margin of -62.1%. Where it stands out: stock pay as % of revenue of 2.6% ranks 20 of 177 application software companies we cover. Where it lags: revenue growth of -3.1% ranks 162 of 184 application software companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 18.2% while net income fell 49.9%: a 32pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 3.1% over the last 12 months.
  • Loss-making. Operating margin is -86.4%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 34.7 points on a year ago.
  • Burning cash. Free cash flow was -62.1% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 76.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 170% and a beta of -0.8 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.54 against an average estimate of -$0.82: beat by 34.6%
Revenue
$2m, up 13.1% on a year earlier
Share reaction
-16.7% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500

BIO KEY International's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.3%
  • 1 week-14.0%
  • 1 month+15.6%
  • This year-54.6%
  • 1 year-68.6%
  • 5 years-99.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.7M
Operating margin
-86.4%
Net margin
-90.1%

Growth

Revenue growth
−3.1%
Change in growth rate
−5.0 pts

Cash

Free cash flow (TTM)
-$4.2M
FCF margin
-62.1%
Stock pay % of revenue
2.6%

Earnings

Last results
August 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Shareholder vote
  3. Agreement
  4. Announcement
  5. Results
  6. Agreement
  7. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

BIO KEY International Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value BIO KEY International Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.87 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.3 ~$9.3–$37 Left out: out of range vs price (0.13x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare BIO KEY International Inc with Application Software in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$2764.80$3816.00$2548.80$1080.00$720.00$633.60$397.80$106.20$30.00$17.10$5.40
Market value$106m$148m$117m$87m$71m$165m$172m$46m$17m$4m$4m
+ Net debt (− = net cash)−$4m−$1m−$288721−$323943$2m−$17m−$8m$407448−$183883$1m−$1m
Enterprise value$101m$147m$117m$87m$73m$149m$164m$47m$17m$5m$2m
Multiples
Price / sales 20.1x49.8x18.6x21.5x31.4x58.3x33.7x6.6x2.2x0.5x0.6x
Price / earnings ———————————
Price / free cash flow ———————————
EV / EBITDA ———n/m———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard BIO KEY International's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -28.7% of total assets over 10 years.

  • Pricing power 9 / 20

    Gross margin has been a median 49.7%, moving by 23.5 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -91.0%; its worst year was -176.4%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -65.3% of revenue.

  • Discipline 5 / 20

    The diluted share count rose 3751.4% over five years; stock-based pay has been a median 6.2% of revenue.

AI disruption exposure: High. In this industry, the core product is information work that AI systems increasingly perform. The score above includes a 15-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.62 — $9m —
Next $0.22 +114% $12m +33%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −29.6% on 90 days ago. In the last 30 days, 1 analyst raised BIO KEY International Inc's forecast and 0 cut it.

Consensus EPS forecast BIO KEY International Inc, last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.30 Current fiscal year, 60 days ago: −$2.30 Current fiscal year, 30 days ago: −$2.30 Current fiscal year, 7 days ago: −$2.30 Current fiscal year, Now: −$1.62 −$1.62

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$2.30
60 days ago −$2.30
30 days ago −$2.30
7 days ago −$2.30
Now −$1.62

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.82 −$0.54 +34.6%
Mar 2026 −$0.60 −$0.13 +77.6%
Sept 2025 −$1.20 −$1.49 −23.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 14, 2026

No numeric guidance in BIO KEY International Inc's latest earnings release (filed August 14, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering BIO KEY International Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
19.4%
of tradable shares
Days to cover
0.03
at average volume
Short interest, 1 month
+5731%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
8.7%
of shares
Employees
41
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BKYI−37%−73%−72%−43%−68%−55%
Industry peers (median)−7%−50%+19%+2%−20%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BKYI33%33%33%33%33%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BKYI−57%−81%−83%−80%−76%−79%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from August 14, 2017 to October 12, 2026. Getting back needed a 314082% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.65 – $10.30
From 52-week high
−76.2%
vs 50-day average
−4.5%
vs 200-day average
−46.1%
Volatility (1 year)
170%
Beta vs S&P 500
-0.79

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±9.3%
After a week
1 up, 11 down
typical move ±10.9%
After a month
1 up, 11 down
typical move ±17.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 −16.7% −0.7% −18.6% −29.2%
May 18, 2026 +7.5% −0.7% +3.5% −8.5%
April 20, 2026 0.0% −0.9% −4.8% −27.5%
March 31, 2026 −11.7% +3.7% −5.0% −16.8%
March 4, 2026 +4.3% +0.1% −7.2% −21.7%
November 14, 2025 0.0% −0.9% −9.3% −32.0%
August 13, 2025 −7.4% +0.4% −8.6% −4.9%
May 15, 2025 0.0% +1.1% −1.2% −1.2%
March 27, 2025 −27.7% −2.3% −35.7% −33.9%
November 15, 2024 −11.8% −0.9% −13.7% −9.8%
August 15, 2024 −7.1% +1.9% −2.1% +18.6%
June 17, 2024 −17.7% +1.1% −21.0% −11.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

BIO KEY International Inc in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) BIO KEY International Inc
$5.5M $6M $6.5M $7M $7.5M $8M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $7.7M Revenue (TTM), FY23 Q4: $7.8M Revenue (TTM), FY24 Q1: $7.8M Revenue (TTM), FY24 Q2: $7M Revenue (TTM), FY24 Q3: $7.3M Revenue (TTM), FY24 Q4: $6.9M Revenue (TTM), FY25 Q1: $6.4M Revenue (TTM), FY25 Q2: $6.9M Revenue (TTM), FY25 Q3: $6.3M Revenue (TTM), FY25 Q4: $5.9M Revenue (TTM), FY26 Q1: $6.5M Revenue (TTM), FY26 Q2: $6.7M $6.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $7.7M
FY23 Q4 $7.8M
FY24 Q1 $7.8M
FY24 Q2 $7M
FY24 Q3 $7.3M
FY24 Q4 $6.9M
FY25 Q1 $6.4M
FY25 Q2 $6.9M
FY25 Q3 $6.3M
FY25 Q4 $5.9M
FY26 Q1 $6.5M
FY26 Q2 $6.7M
Revenue growth, TTM YoY BIO KEY International Inc
-20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 24.1% Revenue growth, TTM YoY, FY23 Q4: 10.5% Revenue growth, TTM YoY, FY24 Q1: 6.7% Revenue growth, TTM YoY, FY24 Q2: -3.9% Revenue growth, TTM YoY, FY24 Q3: -5.1% Revenue growth, TTM YoY, FY24 Q4: -10.6% Revenue growth, TTM YoY, FY25 Q1: -18.0% Revenue growth, TTM YoY, FY25 Q2: -0.8% Revenue growth, TTM YoY, FY25 Q3: -13.4% Revenue growth, TTM YoY, FY25 Q4: -14.3% Revenue growth, TTM YoY, FY26 Q1: 1.9% Revenue growth, TTM YoY, FY26 Q2: -3.1% -3.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 24.1%
FY23 Q4 10.5%
FY24 Q1 6.7%
FY24 Q2 -3.9%
FY24 Q3 -5.1%
FY24 Q4 -10.6%
FY25 Q1 -18.0%
FY25 Q2 -0.8%
FY25 Q3 -13.4%
FY25 Q4 -14.3%
FY26 Q1 1.9%
FY26 Q2 -3.1%
Operating margin (TTM) BIO KEY International Inc
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -144.4% Operating margin (TTM), FY23 Q4: -113.8% Operating margin (TTM), FY24 Q1: -97.7% Operating margin (TTM), FY24 Q2: -98.4% Operating margin (TTM), FY24 Q3: -75.0% Operating margin (TTM), FY24 Q4: -57.9% Operating margin (TTM), FY25 Q1: -65.2% Operating margin (TTM), FY25 Q2: -51.7% Operating margin (TTM), FY25 Q3: -61.5% Operating margin (TTM), FY25 Q4: -115.0% Operating margin (TTM), FY26 Q1: -98.0% Operating margin (TTM), FY26 Q2: -86.4% -86.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -144.4%
FY23 Q4 -113.8%
FY24 Q1 -97.7%
FY24 Q2 -98.4%
FY24 Q3 -75.0%
FY24 Q4 -57.9%
FY25 Q1 -65.2%
FY25 Q2 -51.7%
FY25 Q3 -61.5%
FY25 Q4 -115.0%
FY26 Q1 -98.0%
FY26 Q2 -86.4%
FCF margin (TTM) BIO KEY International Inc
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -54.8% FCF margin (TTM), FY23 Q4: -48.9% FCF margin (TTM), FY24 Q1: -20.3% FCF margin (TTM), FY24 Q2: -40.6% FCF margin (TTM), FY24 Q3: -54.2% FCF margin (TTM), FY24 Q4: -42.2% FCF margin (TTM), FY25 Q1: -63.9% FCF margin (TTM), FY25 Q2: -51.0% FCF margin (TTM), FY25 Q3: -53.0% FCF margin (TTM), FY25 Q4: -78.8% FCF margin (TTM), FY26 Q1: -64.8% FCF margin (TTM), FY26 Q2: -62.1% -62.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -54.8%
FY23 Q4 -48.9%
FY24 Q1 -20.3%
FY24 Q2 -40.6%
FY24 Q3 -54.2%
FY24 Q4 -42.2%
FY25 Q1 -63.9%
FY25 Q2 -51.0%
FY25 Q3 -53.0%
FY25 Q4 -78.8%
FY26 Q1 -64.8%
FY26 Q2 -62.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 4 4 4 2 4 5 3 6 4 2 3 5 7 8 7 6 7
Gross profit 3 3 3 2 3 4 2 3 −0 −0 2 3 5 1 6 5 5
EBITDA −1 −1 0 −2 −2 −2 −4 −4 0 −1 −5 −5 −10 −9 −4 −7 −6
Operating income −1 −1 0 −3 −2 −2 −4 −4 0 −1 −5 −5 −10 −9 −4 −7 −6
Net income −0 −2 0 −3 −2 −2 −4 −4 −7 −15 −10 −5 −12 −9 −4 −7 −6
Diluted EPS −$0.01 −$4.32 $0.00 −$103.68 −$6.48 −$51.84 −$16.02 −$13.68 −$13.14 −$147.78 −$37.44 −$11.70 — — — — —
Growth (year on year)
Revenue — −0.3% +9.3% −48.2% +101.7% +31.3% −43.4% +111.8% −35.8% −43.9% +25.1% +80.3% +37.3% +10.5% −10.6% −14.3% −3.1%
EBITDA — — — — — — — — — <−999% — — — — — — —
Margins
Gross margin 84.1% 76.9% 85.1% 80.5% 81.3% 75.7% 75.5% 48.6% −3.0% −8.5% 72.0% 67.3% 65.2% 18.5% 81.4% 76.9% 81.3%
EBITDA margin −33.5% −40.6% 1.5% −125.5% −49.9% −31.4% −139.6% −67.0% 2.1% −43.5% −180.4% −95.6% −140.7% −112.8% −56.5% −113.6% −85.3%
Operating margin −34.1% −41.5% 0.7% −127.0% −50.9% −32.2% −141.2% −67.8% 0.0% −47.1% −183.4% −96.6% −141.4% −113.8% −57.9% −115.0% −86.4%
Net margin −8.7% −54.1% 0.1% −130.0% −47.0% −35.3% −140.8% −67.8% −169.8% −643.4% −341.0% −99.0% −169.7% −109.9% −62.1% −120.6% −90.1%
Free-cash-flow margin −9.2% −16.5% — −141.7% −62.9% −295.8% −151.2% −41.8% −41.2% −82.9% −175.8% −176.4% −89.9% −48.9% −42.2% −78.8% −62.1%
Cash flow
Cash from operations −0 −1 0 −3 −3 −16 −4 −2 −2 −2 −5 −9 −6 −4 −3 −5 −4
Capital spending 0 0 — 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Free cash flow −0 −1 — −3 −3 −16 −4 −3 −2 −2 −5 −9 −6 −4 −3 −5 −4
Stock-based pay 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0
Free cash flow after stock pay −0 −1 — −3 −3 −16 −5 −4 −3 −3 −6 −9 −7 −4 −3 −5 −4
Balance sheet
Cash 1 0 0 2 1 4 1 0 0 0 17 8 3 1 0 3 1
Total debt 3 1 1 0 0 0 0 — — 2 0 0 3 0 2 1 —
Net debt (negative = net cash) 2 1 1 −2 −1 −4 −1 −0 −0 2 −17 −8 0 −0 1 −1 −1
Diluted shares — — — — — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $7m
Short-term assets $4mLonger-term assets $4m
What it owes, and who funded it · $7m
Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $4m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $135,014 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$6m against $53,411 of interest.

From BIO KEY International Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
39.3%
of revenue
Sales & admin spending
91.1%
of revenue
Days sales outstanding
94 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in application software
Last 12 months unless stated BKYI AUR RYET AZ RYDE NTCL Median
Revenue, last 12 months $7m $7m $7m $8m $10m $10m $482m
Revenue growth, last 12 months −3.1% 250.0% 11.9% 47.0% 42.9% −2.9% 12.0%
Revenue growth, 3-year average −2.6% −61.6% — — — — 11.1%
Revenue growth, latest quarter 13.1% 200.0% — — — — 11.9%
Gross margin 81.3% −285.7% 25.2% 13.8% — 22.8% 69.2%
Operating margin −86.4% <−999% −97.8% −461.4% −50.1% −111.5% 1.1%
Operating margin, 3-year average −78.8% <−999% — — — — −0.8%
Net margin −90.1% <−999% −105.0% −477.6% −139.5% −110.4% 2.1%
Cash from operations / revenue −62.1% <−999% −122.3% −289.9% −188.2% −58.3% 18.2%
Free-cash-flow margin −62.1% <−999% −123.2% −295.6% −188.2% −58.4% 15.0%
Free-cash-flow margin, 3-year average −51.2% <−999% — — — — 16.2%
Stock pay / revenue 2.6% >999% 6.0% 257.7% 88.7% 31.2% 9.3%
Change in share count 76.2% 10.1% 14.1% 73.0% 110.7% 14.2% 2.2%

Median of all 185 companies we cover in application software. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

185 application software companies
Measure Company Peer median Rank
Revenue growth Growth -3.1% 12.0% 162 of 184
Change in growth rate Growth -5.0pp +0.2pp 154 of 184
Gross margin Profitability 81.3% 69.8% 29 of 160
Operating margin Profitability -86.4% 1.1% 152 of 181
Net margin Profitability -90.1% 2.1% 155 of 185
Free-cash-flow margin Cash generation -62.1% 15.2% 156 of 180
Stock pay as % of revenue Cash generation 2.6% 9.3% 20 of 177
Long-term debt as % of assets Balance sheet 9.9% 16.9% 34 of 98
Days sales outstanding Balance sheet 94 days 57 days 132 of 162

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $3.4M 57.7% ▼ 34.0%
Hardware $1.3M 22.6% ▲ 112.5%
Services $1.2M 19.7% ▲ 5.7%
Geography
Region Revenue Share YoY
North America $2.7M 45.0% ▼ 22.9%
EMESA $2.3M 37.9% ▲ 30.9%
Africa $781,766 13.2% ▼ 52.7%
Asia $232,264 3.9% ▲ 154.4%

From BIO KEY International Inc's 10-K filed June 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 14, 2026
  • May 18, 2026
  • April 20, 2026
  • March 31, 2026
  • March 4, 2026
  • November 14, 2025

Recent SEC filings

Data status

When each part of this page on BIO KEY International Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

BIO KEY International Inc in brief

What does BIO KEY International Inc do?
BIO KEY International Inc is a US-listed company in the application software industry. Its financial year ends in December.
What is BIO KEY International Inc's stock ticker?
BIO KEY International Inc trades under the ticker BKYI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is BIO KEY International Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, BIO KEY International Inc reported revenue of $6.7M, 3.1% lower than a year earlier, according to its SEC filings.
What is BIO KEY International Inc's free cash flow?
BIO KEY International Inc's free-cash-flow margin is -62.1% of revenue over the trailing twelve months, ranking 156 of the 180 application software companies we cover.
What is BIO KEY International Inc's market cap?
On December 31, 2025, BIO KEY International Inc's market capitalisation was about $3.6M and net debt of -$1.4M. Market figures come from third-party market data and may be delayed.
Who are BIO KEY International Inc's competitors?
In our Application Software peer group, the companies closest to BIO KEY International Inc are Aurora Innovation, Inc., Ruanyun Edai Technology Inc., A2z Cust2mate Solutions Corp., Ryde Group Ltd and Netclass Technology Inc. The side-by-side comparison below sets their revenue, margins and growth against BIO KEY International Inc's.